当前位置:
X-MOL 学术
›
Nat. Rev. Drug. Disc.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape
Nature Reviews Drug Discovery ( IF 122.7 ) Pub Date : 2024-05-23 , DOI: 10.1038/d41573-024-00085-5 Giacomo Capone , Björn Eriksson , Monique Al , Stan van Belkum , Karl Broich , Maria Lamas , Marianne Lunzer , Lorraine Nolan , Catriona Ester , Juan Garcia Burgos , Laura Pioppo , Ana Zanoletty , Peter Arlett
Nature Reviews Drug Discovery ( IF 122.7 ) Pub Date : 2024-05-23 , DOI: 10.1038/d41573-024-00085-5 Giacomo Capone , Björn Eriksson , Monique Al , Stan van Belkum , Karl Broich , Maria Lamas , Marianne Lunzer , Lorraine Nolan , Catriona Ester , Juan Garcia Burgos , Laura Pioppo , Ana Zanoletty , Peter Arlett
Accelerating Clinical Trials in the EU (ACT EU) is an initiative developed by the European Commission, Heads of Medicines Agencies and the European Medicines Agency to transform the clinical trials landscape in the European Union. It aims to foster regulatory, technological and process innovation to support better, faster and optimized clinical trials.
中文翻译:
加速欧盟临床试验(ACT EU):改变欧盟临床试验格局
加速欧盟临床试验 (ACT EU) 是由欧盟委员会、药品机构负责人和欧洲药品管理局制定的一项举措,旨在改变欧盟的临床试验格局。它旨在促进监管、技术和流程创新,以支持更好、更快和优化的临床试验。
更新日期:2024-05-24
中文翻译:
![](https://scdn.x-mol.com/jcss/images/paperTranslation.png)
加速欧盟临床试验(ACT EU):改变欧盟临床试验格局
加速欧盟临床试验 (ACT EU) 是由欧盟委员会、药品机构负责人和欧洲药品管理局制定的一项举措,旨在改变欧盟的临床试验格局。它旨在促进监管、技术和流程创新,以支持更好、更快和优化的临床试验。